Latest news

Adalvo has been recognised with two prestigious awards at the 2024 Global Generics & Biosimilars Bulletin Awards: Business Development of the Year and Value Added Medicine of the Year.  The Business Development...

At Adalvo we are driven by our commitment to our partner network, dedicated to making a meaningful impact and improving patient lives globally. We are proud to share that Adalvo has been...

Adalvo proudly announces a significant milestone in its operational performance, setting a new record by releasing a total of 221 batches during March 2024, surpassing previous benchmarks by 42%. This achievement showcases...

Adalvo proudly announces its recent induction into Medicines for Europe, a renowned association advancing the generic pharmaceutical sector.    As a member, Adalvo will play a pivotal role in shaping the future...

Adalvo is delighted to announce a significant achievement for January 2024, securing a total of 69 Marketing Authorisation Approvals. This success spans across 18 countries, in collaboration with 12 esteemed strategic partners. During this...

Adalvo and ITP are thrilled to announce the successful implementation of SAP S/4HANA, marking the beginning of a promising journey in digital transformation. This collaboration has laid the foundation for a scalable cloud-based...

Adalvo are thrilled to announce that our much anticipated Padalvo tournament made a spectacular return this year. Padel, one of the world's fastest-growing sports, combines strategy, social interaction, and pure fun....

At Adalvo we are driven by our relentless passion and commitment to our partner network. We tirelessly strive for excellence in all of our endeavors, driven by a deep-rooted passion...

Adalvo is proud to announce the launch of our Q3 2023 Product Dossier. Offering an exclusive glimpse into the advancing strides we have made over the last quarter, reflecting Adalvo's unwavering dedication...

Adalvo is proud to share a significant achievement in our pursuit to making a difference for patients around the world. Last week, the company successfully filed three distinct INN DCP applications for Azelastine+Fluticasone...

We are honored to have been recognized by CPhI Pharma, where our CEO, Anil Okay, has been nominated as a finalist for the CEO of the Year Award!

At Adalvo we are driven by our relentless passion and commitment to our partner network. We tirelessly strive for excellence in all of our endeavors, driven by a deep-rooted passion...

We are humbled and honored to have been recognized by Global Health and Pharma Magazine's 2022 Global Excellence Awards and have been awarded the title of: Most Innovative B2B Pharmaceutical Company, 2022...